Aera Therapeautics
Paul Conrad serves as the Chief Business Officer and Chief Financial Officer at Aera Therapeutics since May 2025. Prior to this role, Paul held various senior positions, including Chief Business Officer, Corporate Secretary, and Treasurer at NextPoint Therapeutics, and Corporate Strategy Advisor at Apic Bio. Paul also contributed to bluebird bio as Vice President of Corporate Development, led immunology and Heme/Onc transactions at Shire, and served as Senior Director of Global Business Development at both Baxalta and Baxter International Inc. With a background in business development, technology strategy, and program management, Paul has experience from AMAG Pharmaceuticals and Taligen Therapeutics. Paul holds an MBA from Harvard Business School, a BSE in Chemical Engineering from Princeton University, and a PhD in Chemical Engineering from the University of Wisconsin-Madison.
This person is not in any teams
This person is not in any offices
Aera Therapeautics
Aera was founded with a vision to unlock the potential of genetic medicines across a broad range of modalities and therapeutic areas. Our protein nanoparticle (PNP) delivery platform leverages the discovery of endogenous, human proteins that can self-assemble to form capsid-like structures and that can package and transfer nucleic acid cargo. This platform has the potential to address many of the limitations of today’s delivery technologies and to enable various genetic medicine modalities.